- Truffle investment
- € 25M
Vexim is working on the development and commercialization of a revolutionary vertebral implant for the treatment of vertebral fractures by minimally invasive surgery.
As with most of the companies in its portfolio, Truffle Capital supported the company's development until the technology was commercialized. This model allows a consistent execution of the business plan, an optimal alignment of the management teams with Truffle Capital and gives the CEO the opportunity to focus his efforts on the technical and commercial success of the project.
They talk about it
The company's flagship product is SpineJack, an implant that can repair a serious vertebral fracture in 30 minutes. A surgeon can insert this prosthesis into the spine through a simple small hole.
Truffle Capital alongside Banexi finances the launch of SpineJack on the European market
CE marking and marketing of SpineJack®
Vexim raised €11 million for its IPO
Strong adoption of SpineJack® by spine surgeons in France, Europe and other countries around the world. Vexim obtains FDA approval to market its Masterflow™ injection system in the United States
Acquisition of Vexim by Stryker for $221 million
Authorization to market spineJack in the United States